HC Wainwright Lowers Earnings Estimates for COMPASS Pathways

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Equities research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for shares of COMPASS Pathways in a report issued on Tuesday, July 15th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.38) per share for the quarter, down from their previous estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways’ Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at $0.04 EPS and FY2029 earnings at $1.59 EPS.

Several other equities analysts have also commented on CMPS. Evercore ISI restated an “in-line” rating and set a $6.00 price target (down previously from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.00.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $3.88 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.18 and a quick ratio of 10.18. The firm has a market capitalization of $363.01 million, a PE ratio of -1.95 and a beta of 2.12. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $8.54. The business’s fifty day moving average price is $3.94 and its two-hundred day moving average price is $3.77.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03.

Hedge Funds Weigh In On COMPASS Pathways

Several large investors have recently bought and sold shares of the stock. Wealthfront Advisers LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at $43,000. Simplify Asset Management Inc. bought a new stake in COMPASS Pathways in the fourth quarter worth about $54,000. EntryPoint Capital LLC lifted its holdings in COMPASS Pathways by 55.2% in the 4th quarter. EntryPoint Capital LLC now owns 65,519 shares of the company’s stock valued at $248,000 after acquiring an additional 23,311 shares during the last quarter. BIT Capital GmbH bought a new position in shares of COMPASS Pathways during the 4th quarter valued at about $437,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of COMPASS Pathways in the 4th quarter worth approximately $83,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.